Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real World Evidence Study of the Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir Without Ribavirin in Patients With Chronic HCV Gt1b Infection and Compensated Liver Cirrhosis in the RussIan FederaTion- An ObseRvational, MultI-CeNter Study (CITRIN)

NCT03053180 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03053180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03053180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real World Evidence Study of the Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir Without Ribavirin in Patients With Chronic HCV Gt1b Infection and Compensated Liver Cirrhosis in the RussIan FederaTion- An ObseRvational, MultI-CeNter Study (CITRIN)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
March 20, 2017
Completion date
December 18, 2017
Enrollment
60 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c